CAR T-cell Therapy in Review 2022: Updates in Treatment

Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX

Recorded on December 16, 2022


Sattva S. Neelapu, MD
Sattva S. Neelapu, MD
Professor and Deputy Chair
Department of Lymphoma and Myeloma
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Chimeric antigen receptor (CAR) T-cell therapy has generated impressive results in hematologic malignancies, with many drugs still in clinical trials. In this episode, Dr. Sattva S. Neelapu from MD Anderson Cancer Center, joins us to discuss updates on CAR T-cell therapy from the 2022 American Society of Hematology (ASH) Annual Meeting. Dr. Neelapu also provides a high-level overview of how CAR T-cell therapy works, including the manufacturing process, and discusses the risk of recurrence following therapy, risk for patients in the era of COVID-19, secondary cancers, associated costs, roadblocks to therapy, and why early referral matters. Tune in to this informative podcast episode to learn more!

Podcast: Play in new window | Download (Duration: 32:46 — 45.0MB)

This podcast episode is supported by Allogene Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Janssen Oncology & Legend Biotech, Kite, A Gilead Company and Novartis Oncology.